Different probiotic formulations in ulcerative colitis: A bayesian network meta-analysis
DOI:
https://doi.org/10.54844/md.2022.0286Keywords:
probiotic, ulcerative colitis, network meta-analysisAbstract
Background: To assess the efficacy and safety of probiotic formulations for the induction of remission in people with ulcerative colitis (UC). Methods: The databases of China national knowledge infrastructure (CNKI), Wanfang Data, Excerpta Medica Database (Embase), Pubmed, and Cochrane Library were searched until May 31, 2022 for randomized clinical trials (RCTs) of patients with UC. Studies had to include 5-aminosalicylate compounds (5-ASAs) as conventional therapy (CON), and 4 listed probiotic formulations used as add on therapy. Trials that recruited patients who was receiving any other treatment were excluded. A network meta-analysis was performed to access and compare different probiotic formulations. Results: 38 RCTs were included. The probiotic formulations participants received included Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Tablets (SLK), Bifid Triple Viable Capsule (BIFICO), Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules (MCA) and Bacillus licheniformis Granules (ZCS). The results of the network meta-analysis indicate that patients receiving SLK + CON (summary relative risk 1.23, 95% confidence interval 1.14 to 1.33), BIFICO + CON (1.24, 1.16 to 1.32) and MCA + CON (1.16, 1.09 to 1.24) showed a significant difference from CON in overall efficacy, SLK + CON had the highest probability of being the best treatment (surface under the cumulative ranking curve [SUCRA], 0.88). In Mayo score, SLK + CON (standardised mean difference [SMD], 1.73, 0.66 to 2.93), BIFICO + CON (1.70, 0.51 to 2.91) showed a significant difference from CON, and SLK + CON had the highest probability of being the best treatment (SUCRA, 0.83). Except that MCA + CON (relative risks [RR], 0.64, 0.41 to 0.98) showed a lower probability of adverse events compared with CON, there was no significant difference between the other pairwise comparison in terms of safety. Conclusion: Probiotic formulations confer an added benefit in inducing remission combining with 5-ASA over 5-ASA alone. SLK shows advantages in overall efficacy and Mayo score compared with the others.
References
Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94(7):1357–1373.
Monstad IL, Solberg IC, Cvancarova M, et al. Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study. J Crohns Colitis. 2020;15(6):969–979.
Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770.
Kaur L, Gordon M, Baines PA, Iheozor-Ejiofor Z, Sinopoulou V, Akobeng AK. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;3(3):CD005573.
Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;(11):1617–1623.
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;62(11):777–784.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;17(26):1625–1629.
Tatiya-Aphiradee N, Chatuphonprasert W, Jarukamjorn K. Immune response and inflammatory pathway of ulcerative colitis. J Basic Clin Physiol Pharmacol. 2018;0(1):1–10.
Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. John Wiley & Sons. 2019.
Jackson D, Riley RD. A refined method for multivariate meta-analysis and meta-regression. Stat Med. 2014;3(4):541–554.
Tian Y, Liu Y. [Effects of Bifidobaterium quadruple live bacteria tablets and Bifidobacterium triple live bacteria tablets on intestinal bio-barrier in patients with moderate active ulcerative colitis]. Chin J Integr Med Tradit and West on Dig. 2020;28(5):323–327.
Wang SJ, Cui GL. [Effect of viable bifidobacterium quadruple combination use in treating parents with ulcerative colitis and its influence on serum IL-17,TNF-a expression]. Anhui Med and Pharm J. 2021;25(5):4.
Wang YB, Chen X. [Recovery effect of teteralogy of Viable Bifidobacterium Tablets combined with Mesalazine on oxidative stress injury of intestinal mucosa of patients with ulcerative colitis]. Chin J Microecology. 2020;32(3):286–289.
Zhang J. [Effect of Bifidobacterium quadruple live bacteria on Mayo score and serum levels of hs-CRP, IL-4, and IL-8 in patients with mild to-moderate ulcerative colitis]. World Chin J Dig. 2018;26(6):373–377.
Yue YY, Zhang Q, Lin LJ. [Efficacy of bifidobacterium tetrameric viable flakes combined with mesalazine on mild to moderate ulcerative colitis]. Pract Pharm Clin Remedies. 2017;20(5):517–520.
Che J, Jia ZB, Wang YX, et al. [Effect of amino salicylic acid combined with probiotics for the maintenance treatment of ulcerative colitis]. Chin J Gastroenterol Hepatol. 2016;25(9):1047–1049.
Wang YD, Chen H. [Clinical observation of mesalazine combined with Bifidobacterium tetravaccine (live) in the treatment of ulcerative colitis]. Chin Pharm. 2016;27(3):326–328.
Xu JY, Wu JY. [Protection Effect of Mesalazine Combined with Bifidobacterium Tetravaccine Tablets on Lipid Peroxidation Damage of Patients with Ulcerative Colitis]. Chin J Pharmacoepidemiol. 2015;24(12):712–714.
Wang JN, Sun MJ, Song NN. [Therapeutic effect of siliankang combining with mesalazine in treatment of mild to moderate ulcerative colitis]. J Trop Med. 2014;14(12):1582–1584.
Xie HQ. [Observation on the therapeutic effect of siliankang combined with mesalazine on 24 cases of ulcerative colitis]. Chin J Coal Ind Med. 2012;15(8):1176–1178.
Wang ZQ. [Clinical Observation of SiLianKang and Salicylazosulfapyridine in Treatment of Ulcerative Colitis]. Occup Health. 2010;26(8):953–954.
Wei SZ, Tian SY, Zheng GQ, Kong Y, Song H, Zhang XG. [Effect and mechanisms of action of Siliankang as an adjuvant therapy for ulceraitve colitis]. Chin J Microecology. 2009;7:641–642.
Wu N, Li D, Cui LJ, Ma HJ. [Clinical Study of Bifidobacterium Triple Viable Combined with Mesalazine in the Treatment of Ulcerative Colitis]. Chin Pharm. 2021;30(2):74–76.
Mu YT, Yang SX, Niu FY. [Regulating effect of Bifidobacterium triple viable capsules on helper T cell 17/regulatory T cell balance in patients with ulcerative colitis]. J Clin Med in Prac. 2021;25(18):76–79.
Duan TN, Liu F. [Clinical effect of mesalazine enema liquid combined with bifid triple viable capsules dissolving at intestines on ulcerative colitis and its influence on the levels of inflammatory factors in patients]. Chin Med. 2021;4(4):579–582.
Li YZ. Effect of mesalazine combined with viable bifidobacterium quadruple tablets on inflammatory factors in patients with ulcerative colitis. J Med Forum. 2019,40(01):39-40.
Luo H. [Clinical study of bifidobacterium combined with mesalazinein treatment of ulcerative colitis]. Drug Eval Res. 2019;42(10):2029–2032.
Mi C, Liu HY, Li YC, Jia A, Song ZJ. [Clinical Efficacy of Siliankang Combining with Mesalazine in Treatment of Ulcerative Colitis and Effects on Intestinal Mucosa TLR4 and NF-κb Expressions and Intestinal Microflora]. Prog in Mod Biomed. 2018;18(1):86–89.
Huang M, Chen ZQ, Lang CH, et al. Efficacy of mesalazine in combination with bifid triple viable capsules on ulcerative colitis and the resultant effect on the inflammatory factors. Pak J Pharm Sci. 2018;31(6(Special)):2891–2895.
Feng XQ, Liang C, Liu R, Zhang L. [Effect of Bifidobacterium Triple Viable Capsule Combined with Mesalazine on Immune Function and Intestinal Mucosa Barrier Function in Patients with Ulcerative Colitis]. Int J Dig Dis. 2018;38(2):144–147.
Hu L, Lian H, Zhou T. [Effect of Bifico combined with mesalazine on the levels of serum inflammatory factors and COX-2 in patients with ulcerative colitis]. Pract J Clin Med. 2018;15(1):76–79.
Mao LX, Guo YC, Qian J. [Clinical Observation of Bifid Triple Viable Capsule in the Treatment of Ulcerative Colitis]. Chin Pharm. 2015;26(36):5095–5096.
Li YX, Song Y, Yao J, Zhang R. [Influence of Bifidobacterium on immune function and Fas/FasL expression of patients with ulcerative colitis]. J Hainan Med Univ. 2015;21(2):184–187.
Zhang C, Zhou YY. [Evaluation of the Efficacy of Bifid Triple Viable Capsule Combined with Mesalazine in the Treatment of Ulcerative Colitis]. J Clin Research. 2014;31(4):696–698.
Shi YH, Liu HL, Huang ZG, Liu ZJ. [Clinical effects of sulfasalazine combined with live combined bifidobacterium lactobacillus and enterococcus capsules in patients with ulcerative colitis]. Chin J New Drugs Clin Rem. 2010,29(10):783-785.
Zhang XB, Yang XW, Dang HJ, et al. [IL-8 and TNF-α Expression changes of mesalazine and MECHANGAN capsule in serum of patients with ulcerative colitis]. Hebei Med. 2010;32(5)589–590.
Lu Y, Lei XW. [Clinical effect of Olsalazine combined with Meichang’an in treating ulcerative colitis]. J Reg Anat and Oper Surg. 2011;20(3):292–293.
Tan Y, Zheng CQ. [Clinical observation of Bacillus licheniformis combined with mesalazine in treatment of active ulcerative colitis]. Chin J Clin Pharmacol. 2018;3(7):1695–1701.
Zheng XJ, Zheng HY, Luo L, Chen Y. [Clinical efficacy of Bacillus subtilis and Enterococcus faecium enteric-coated capsules combined with mesalazin enteric-coated tablets in the treatment of the patients with ulcerative colitis]. Chin J Clin Pharmacol. 2016;32(3):212–214.
Weng Y. [Therapeutic Effect of Bacillus Subtilis combined with Mesalazine Enteric-coated Capsules on Patients with Ulcerative Colitis and the effects of serum SOD MDA and TNF-alpha]. Hebei Med. 2018;24(12):1945–1947.
Qing R, Zhu SJ, Wang GK. [64 Cases of Ulcerative Colitis Treated with Bacillus subtilis Dual Viable Enteric coated Capsules Combined with 5-Aminosalicylic Acid]. Guangdong Med J. 2010;31(13):1739–1740.
Zhao JL, Zhang HM. [Effect of live combined bacillus subtilis and enterococcus faecium enteric-coated capsules on ulcerative colitis]. J Xinxiang Med Univ. 2016;3(11):983–986.
Shi XH, Tan FP, Jiang WH. [Bacillus subtilis and Enterococcus faecium enteric-coated capsules combined with mesalazine for treatment of patients with ulcerative colitis: Efficacy and impact on serum levels of SOD, MDA, interleukins, and TNF-α]. World Chin J Digestology. 2018;26(12):748–754.
Tian J, Wang L, Xu N. [Efficacy of mesalazine and Bacillus subtilis and Enterococcus faecium enteric-coated capsules in patients with mild to moderate ulcerative colitis]. Pract Pharm Clin Remedies. 2019;22(3):296–299.
Hu HP, Chen JL, Zhang L. [Clinical study on the efficacy of mesalazine and live combined Bacillus subtilis and Enterococcus faecium enteric-coated capsules in the treatment of ulcerative colitis]. J Hainan Med Univ. 2016;22(16):1800–1802.
Gu ZX. [Clinical efficacy and safety of mesalazine combined with metoprolol in the treatment of ulcerative colitis]. Mod J Integr Tradit Chin and West Med. 2012;21(21):2346–2347.
Jiang XL. [Efficacy of combination of mesalazine and Bacillus subtilis live bacteria enteric coated capsules in the treatment of ulcerative colitis]. Chin Remedies & Clin. 2013;13(3):386–387.
Zhang H, Xu LH, Yang D, Han JX, Zhu XJ, Zhang YD. [Effect of mesalazine assisted microecological preparation on ulcerative colitis in the elderly and its influence on inflammatory factors of immune function]. Chin J Clin Gastroenterol. 2021;(4):033.
Liu H, Yao P. [Treatment of ulcerative colitis with a microecological preparation comprising Bacillus subtilis and Enterococcus: An analysis of 58 cases]. World J Gastroenterol. 2012;20(19):1796–1799.
Javed NH, Alsahly MB, Khubchandani J. Oral Feeding of Probiotic Bifidobacterium infantis: Colonic Morphological Changes in Rat Model of TNBS-Induced Colitis. Scientifica. 2016;2016:9572596.
Kumar CSVS, Reddy KK, Boobalan G, et al. Immunomodulatory effects of Bifidobacterium bifidum 231 on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. Res Vet Sci. 2017;110:40–46.
Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20(10): 1133–1141.
Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. WJG. 2010;16(33):4145.
Li SY, Yin Y, Xiao D, Zou Y. Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients. BMC Gastroenterol. 2021;21(1):314.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Microbiota & Diseases
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
